HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by De Waele, M. Articles by Van Schil, P. Search for Related Content PubMed PubMed Citation Articles by De Waele, M. Articles by Van Schil, P. Related Collections Lung - cancer Mediastinum

Eur J Cardiothorac Surg 2006;29:240-243
© 2006 Elsevier Science NL

Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy

^a Department of Thoracic and Vascular surgery, University Hospital of Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium
^b Department of Pulmonary Medicine, University Hospital of Antwerp, Wilrijkstraat 10, 2650 Edegem, Belgium
^c Department of Pulmonary Medicine, Hospital AZ Heilige Familie, Reet, Belgium
^d Department of Pulmonary Medicine, Hospital De Pelikaan, Temse, Belgium
^e Department of Pulmonary Medicine, Hospital Sint-Jozef, Bornem, Belgium

Received 31 August 2005; received in revised form 30 September 2005; accepted 7 October 2005.

^_* Corresponding author. Tel.: +32 3 8214360; fax: +32 3 8214396. (Email: paul.van.schil{at}uza.be).

Objective: Remediastinoscopy is a valuable tool in restaging non-small cell lung cancer after induction therapy for mediastinal nodal involvement as it provides pathological evidence of response and may select patients for subsequent thoracotomy. However, long-term survival data after remediastinoscopy are scarce. Methods: From November 1994 to April 2003, a remediastinoscopy was performed in 32 patients (29 men, 3 women) after induction therapy for locally advanced non-small cell lung cancer. Mean age was 67.8 years (range, 47–83). Neoadjuvant chemotherapy was given in 26 patients and chemoradiotherapy in 6. Follow-up data were completed in January 2005. Results: Remediastinoscopy was technically feasible in all patients. There were five false-negative remediastinoscopies, resulting in a sensitivity of 71%, specificity of 100% and accuracy of 84%. Follow-up was complete in all patients. Median survival time for the whole group was 21 months (95% confidence interval [CI] 9–33). Median survival time in patients with a positive remediastinoscopy was 7 months (95% CI 5–9), with a negative remediastinoscopy 41 months (95% CI 13–69), and with a false-negative remediastinoscopy 24 months (95% CI 5–43). The difference between positive and negative remediastinoscopies was highly significant (p = 0.003). In the combined group of patients with positive and false-negative remediastinoscopies (n = 17), median survival time was 8 months (95% CI 3–13). The difference with negative remediastinoscopy remained significant (p = 0.012). In a multivariate analysis, including sex, age, histology and nodal status at repeat mediastinoscopy, only nodal status was a significant independent prognostic factor (p = 0.015). Conclusions: Remediastinoscopy is a valuable restaging procedure after induction therapy. Prognosis is poor in patients with persisting mediastinal nodal involvement, proven at repeat mediastinoscopy.

Key Words: Remediastinoscopy • Lung cancer • Staging • Induction therapy

This article has been cited by other articles:

				F. J.F. Herth, J. T. Annema, R. Eberhardt, K. Yasufuku, A. Ernst, M. Krasnik, and R. C. Rintoul Endobronchial Ultrasound With Transbronchial Needle Aspiration for Restaging the Mediastinum in Lung Cancer J. Clin. Oncol., July 10, 2008; 26(20): 3346 - 3350. [Abstract] [Full Text] [PDF]

				M. De Waele, M. Serra-Mitjans, J. Hendriks, P. Lauwers, J. Belda-Sanchis, P. Van Schil, and R. Rami-Porta Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 824 - 828. [Abstract] [Full Text] [PDF]

				P. E. Van Schil and M. De Waele A second mediastinoscopy: how to decide and how to do it? Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 703 - 706. [Abstract] [Full Text] [PDF]

				A. Marra, L. Hillejan, S. Fechner, and G. Stamatis Remediastinoscopy in restaging of lung cancer after induction therapy. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 843 - 849. [Abstract] [Full Text] [PDF]

				F. C. Detterbeck, M. A. Jantz, M. Wallace, J. Vansteenkiste, and G. A. Silvestri Invasive Mediastinal Staging of Lung Cancer: ACCP Evidence-Based Clinical Practice Guidelines (2nd Edition) Chest, September 1, 2007; 132(3_suppl): 202S - 220S. [Abstract] [Full Text] [PDF]

				P. Granone, P. Van Schil, and A. Cesario Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A closer look at redo mediastinoscopy J. Thorac. Cardiovasc. Surg., January 1, 2007; 133(1): 275 - 276. [Full Text] [PDF]

				P. Van Schil and G. Stamatis Sensitivity of Remediastinoscopy: Influence of Adhesions, Multilevel N2 Involvement, or Surgical Technique? J. Clin. Oncol., November 20, 2006; 24(33): 5338 - 5338. [Full Text] [PDF]